Back to Search Start Over

The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade.

Authors :
Kalla M
Hao G
Tapoulal N
Tomek J
Liu K
Woodward L
Dall'Armellina E
Banning AP
Choudhury RP
Neubauer S
Kharbanda RK
Channon KM
Ajijola OA
Shivkumar K
Paterson DJ
Herring N
Source :
European heart journal [Eur Heart J] 2020 Jun 14; Vol. 41 (23), pp. 2168-2179.
Publication Year :
2020

Abstract

Aims: ST-elevation myocardial infarction is associated with high levels of cardiac sympathetic drive and release of the co-transmitter neuropeptide Y (NPY). We hypothesized that despite beta-blockade, NPY promotes arrhythmogenesis via ventricular myocyte receptors.<br />Methods and Results: In 78 patients treated with primary percutaneous coronary intervention, sustained ventricular tachycardia (VT) or fibrillation (VF) occurred in 6 (7.7%) within 48 h. These patients had significantly (P < 0.05) higher venous NPY levels despite the absence of classical risk factors including late presentation, larger infarct size, and beta-blocker usage. Receiver operating curve identified an NPY threshold of 27.3 pg/mL with a sensitivity of 0.83 and a specificity of 0.71. RT-qPCR demonstrated the presence of NPY mRNA in both human and rat stellate ganglia. In the isolated Langendorff perfused rat heart, prolonged (10 Hz, 2 min) stimulation of the stellate ganglia caused significant NPY release. Despite maximal beta-blockade with metoprolol (10 μmol/L), optical mapping of ventricular voltage and calcium (using RH237 and Rhod2) demonstrated an increase in magnitude and shortening in duration of the calcium transient and a significant lowering of ventricular fibrillation threshold. These effects were prevented by the Y1 receptor antagonist BIBO3304 (1 μmol/L). Neuropeptide Y (250 nmol/L) significantly increased the incidence of VT/VF (60% vs. 10%) during experimental ST-elevation ischaemia and reperfusion compared to control, and this could also be prevented by BIBO3304.<br />Conclusions: The co-transmitter NPY is released during sympathetic stimulation and acts as a novel arrhythmic trigger. Drugs inhibiting the Y1 receptor work synergistically with beta-blockade as a new anti-arrhythmic therapy.<br /> (© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Details

Language :
English
ISSN :
1522-9645
Volume :
41
Issue :
23
Database :
MEDLINE
Journal :
European heart journal
Publication Type :
Academic Journal
Accession number :
31834357
Full Text :
https://doi.org/10.1093/eurheartj/ehz852